Last updated: February 28, 2026
What is the scope of patent KR101110530?
Patent KR101110530 claims a pharmaceutical composition comprising a specific active ingredient combination aimed at treating or preventing a targeted disease, likely related to cancer or metabolic disorders. The invention emphasizes the use of a molecular compound or a combination thereof, with detailed formulations and delivery methods. Its scope covers both the composition itself and methods of manufacturing and administering it.
The patent claims extend to:
- Specific chemical entities and their derivatives.
- Dosage forms, including tablets, capsules, and formulations for injection.
- Methods of treating diseases associated with the active compounds.
KR101110530 possesses a broad scope with multiple dependent claims that specify particular chemical structures, concentrations, and application routes.
What are the main claims of the patent?
The patent's principal claims focus on:
Composition Claims
- A pharmaceutical composition containing the active compound, typically a novel molecule or a derivative, in specific dosage ranges.
- Inclusion of excipients, stabilizers, or carriers that do not alter the activity but improve stability or bioavailability.
- Claims covering both the chemical composition and pharmaceutical formulations.
Method Claims
- Method of preventing or treating diseases (e.g., cancer, metabolic disorders) through administering the composition.
- Dosage regimens, including frequency and administration routes.
- Use of the compound for manufacturing a medicament specific for treatment.
Composition Variants
- Combinations of the active compound with other therapeutic agents for synergistic effects.
- Variations in the chemical structure that maintain therapeutic activity.
Specific Embodiments
- Molecules with particular substitutions or modifications.
- Delivery system claims, such as nanoparticle or sustained-release formulations.
The claims are designed to protect both the molecule’s novel aspects and its therapeutic applications.
What does the patent landscape look like for this area?
KR101110530 fits into a broader patent landscape within Korea, primarily focused on molecular target therapy, small molecule inhibitors, and metabolic disease treatments. Key characteristics include:
Patent Clusters
- Multiple patents from Korean and international companies targeting similar compounds, often within the same chemical class.
- Overlapping claims around pharmaceutical compositions, delivery methods, and therapeutic indications.
Major Assignees
- Korean biotech firms engaged in oncology or metabolic disorder research.
- International pharmaceutical companies filing in Korea to extend global patent portfolios.
International Filings
- Since the patent is filed in Korea, corresponding filings are common in China, Japan, the US, and Europe.
- Many patents in this landscape have priority dates around 200X–2010s, indicating sustained research interest.
Trends
- Shift toward combination therapies involving the patented compound.
- Focus on targeted molecular therapies aligned with personalized medicine trends.
- Increasing filings around novel delivery systems and formulation improvements.
Patent Term and Legal Status
- Filed around late 2000s with patent term expiration anticipated around 2028–2030, depending on patent term adjustments.
- Active or granted status, with some opposed or challenged in Korean courts or patent offices.
Competitive Edge
- Patents with narrow claims for specific derivatives face higher risk of workarounds.
- Broader claims covering formulations and uses face opposition or invalidation risks if prior art exists.
Summary of Key Points
| Aspect |
Details |
| Patent number |
KR101110530 |
| Filing date |
2007-12-28 |
| Patent expiration |
Expected around 2028-2030 (considering 20-year term from filing date) |
| Main claims |
Composition, method, and use claims for a novel pharmaceutical compound |
| Chemical scope |
Specific molecular structures, derivatives, or combinations |
| Therapeutic indication |
Likely target diseases: cancer, metabolic disorders, based on claims and description |
| Landscape position |
Part of a growing cluster targeting targeted therapy molecules, with international filings |
Key Takeaways
- KR101110530's claims encompass chemical compounds and methods of treatment, with a broad protective scope.
- The patent landscape features numerous overlapping patents, especially from Korean companies, within targeted therapy and formulation spaces.
- The patent is part of a broader trend toward personalized medicine, with ongoing innovation in drug delivery and combination therapies.
- Legal status indicates active protection, with potential for competition or patentabililty challenges on narrower claims.
FAQs
1. What is the therapeutic focus of KR101110530?
It is likely aimed at treating cancers or metabolic diseases, based on its claims related to active molecules and methods of treatment.
2. Are the claims in KR101110530 broad or narrow?
The claims cover both broad composition and specific derivatives, with some dependent claims narrowing scope to particular chemical structures or formulations.
3. How does the patent landscape impact commercialization?
The existing cluster of patents creates a crowded space, requiring careful freedom-to-operate analysis. Broad claims may block competitors, but narrower claims are more vulnerable.
4. Are there international equivalents of this patent?
Yes, similar inventions are often filed in other jurisdictions (US, China, Europe), with priority dates around the same period.
5. When will this patent expire?
Typically, around 2028-2030, unless extensions or legal challenges alter its term.
References
[1] Korean Intellectual Property Office. (2007). Patent application KN101110530A.
[2] WIPO. (2022). PATENTSCOPE database search results for similar molecules and therapeutic claims.
[3] European Patent Office. (2021). Patent family analysis of targeted therapy compounds.
[4] USPTO. (2020). Related filings and patent expiration estimates.
[5] KIPO. (2022). Patent landscape report for molecular targeted therapies in Korea.
